Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6260834 | 0.78 | MGLL (0.32) | — | |
| SCHEMBL725035 | 0.75 | — | — | |
| SCHEMBL1766181 | 0.75 | PTGS1 (0.36) | PTGS1PTGS2 | |
| Cyclohexane SCHEMBL3760865 | 0.72 | LMNA (0.50) | — | |
| SCHEMBL45794 | 0.71 | PTGS1 (0.33) | PTGS1PTGS2 | |
| SCHEMBL1682194 | 0.68 | LMNA (0.56) | — | |
| SCHEMBL1019147 | 0.66 | — | — | |
| SCHEMBL28668492 | 0.66 | PTGS1 (0.56) | PTGS1PTGS2 | |
| SCHEMBL9841169 | 0.65 | PTGS1 (0.37) | PTGS1PTGS2 | |
| SCHEMBL28600387 | 0.64 | ALDH1A1 (0.38) | PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11185594-B2 | (Anti-HER2 antibody)-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-11-30 | — | — | US | disclosed |
| EP-3130608-B1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO CO LTD (JP) | 2019-09-04 | — | — | EP | disclosed |
| EP-3130608-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | Daiichi Sankyo Co., Ltd. (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-02-09 | — | — | US | disclosed |
| US-8323645-B2 | Antibodies that bind OV064 and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20090208489-A1 | Antibodies That Bind OV064 and Methods of Use Therefor | MILLENNIUM PHARMACEUTICALS, INC. INTELLECTUAL PROPERTY GROUP (US) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | ERBB2, EGFR, LANCL2 | PTGS1 2252/4885PTGS2 1946/4885 |
| US-11185594-B2 | (Anti-HER2 antibody)-drug conjugate | ERBB2, EGFR, LANCL2 | PTGS1 2252/4885PTGS2 1946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.